pat1

PAT1inh-B01, a selective SLC26A6 inhibitor, impedes PAT1 (a Cl- HCO3- exchanger) activity, with an IC50 of 350 nM, effectively inhibiting anion exchange. It also obstructs fluid absorption in the small intestine and is utilized in the study of small intestinal hyposecretory disorders [1].

PAT1inh-A0030 is a selective inhibitor of PAT1 (SLC26A6) with an IC 50 value of 1.0 μM. It inhibits fluid absorption in the ileum of wild-type and cystic fibrosis (CF) mice (CftrdelF508 delF508) in a closed-loop model of intestinal fluid absorption and can be used in the study of intestinal diseases related to CF [1].

Arecaidine hydrochloride may have carcinogenesis.

Arecaidine hydrobromide is the salt form of Arecaidine, a pyridine alkaloid with potent GABA uptake inhibitory properties that acts as a substrate for H+-coupled amino acid transporter protein 1 (PAT1, SLC36A1) to competitively inhibit the uptake of L-proline.